Recent Events & Catalysts
Axsome Therapeutics, Inc. (AXSM) — real, dated facts. Not a claim about what caused any single day's price move.
Committee Signals
Proprietary signals generated by the Innellis AI committee — score changes, rating shifts, and analyst disagreements.
No committee signals recorded yet.
News
Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition
SeekingAlpha · today
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $251
Benzinga · today
RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $297
Benzinga · today
Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results
Benzinga · today
Guggenheim Maintains Buy on Axsome Therapeutics, Raises Price Target to $275
Benzinga · today
Wells Fargo Maintains Overweight on Axsome Therapeutics, Raises Price Target to $256
Benzinga · today
Target To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · today
Needham Maintains Buy on Axsome Therapeutics, Raises Price Target to $268
Benzinga · today
SEC Filings (90 days)
Results of operations (earnings release), Other events, Financial statements and exhibits
Filed 2026-08-10 · 1d ago · Material
Other events, Financial statements and exhibits
Filed 2026-07-15 · 27d ago
Departure/appointment of directors or officers, Financial statements and exhibits
Filed 2026-06-09 · 63d ago
Submission of matters to a vote of security holders, Financial statements and exhibits
Filed 2026-06-09 · 63d ago
Other events, Financial statements and exhibits
Filed 2026-06-03 · 69d ago
Earnings
No recent earnings data available.
Latest Analyst Action
No recent analyst actions available.